Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like FDA Grants Orphan Drug Designation To Prometic's PBI-4050 Drug For The Treatment Of Alstr??m Syndrome March 2, 2017 Gelesis Secures $30 Million to Support Potential Approval of Weight Loss Drug February 28, 2018 Could J&J’s Deal With Theravance Develop a Replacement for Remicade in IBD? February 20, 2018
FDA Grants Orphan Drug Designation To Prometic's PBI-4050 Drug For The Treatment Of Alstr??m Syndrome March 2, 2017